- Conditions
- High Grade Glioma, Anaplastic Astrocytoma
- Interventions
- DB107-RRV, DB107-FC
- Drug
- Lead sponsor
- Ashish Shah
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer
- Interventions
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Drug
- Lead sponsor
- BioNTech Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
- Conditions
- Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
- Interventions
- Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Encino, California • Fresno, California + 24 more
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia
- Interventions
- PRI-724
- Drug
- Lead sponsor
- Prism Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more
- Conditions
- Chronic HIV Infection
- Interventions
- 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more
- Conditions
- Focal Onset Seizures
- Interventions
- JNJ-40411813, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Acute Myeloid Leukemia, IDH1 Mutation
- Interventions
- Olutasidenib, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Justin Watts, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Leukemia, Myeloid, Chronic
- Interventions
- Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Trametinib, Ruxolitinib, Retifanlimab
- Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Tinnitus
- Interventions
- Nortriptyline, Topiramate, Paroxetine, Verapamil
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 25 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Living Healthier with Diabetes
- Behavioral
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Anti-oxidant and micronutrient, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Evaluation of Laparoscopic Hysterectomy Simulator
- Interventions
- Laparoscopic Hysterectomy trainer
- Procedure
- Lead sponsor
- Unity Health Toronto
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Seattle, Washington
- Conditions
- High Grade Glioma
- Interventions
- Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
- Procedure · Drug · Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy
- Interventions
- EyePromise DVS, EyePromise DVS plus EyePromise EZTears
- Dietary Supplement
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Colo-rectal Cancer
- Interventions
- Arfolitixorin, Leucovorin
- Drug
- Lead sponsor
- Isofol Medical AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 15 more
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Interventions
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 56 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Anaheim, California • San Diego, California + 28 more
- Conditions
- Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
- Interventions
- torcetrapib/atorvastatin, simvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 46 more
- Conditions
- Bereavement, Grief, Psychological Distress, Well Being
- Interventions
- Rise & Renew Hybrid Grief Support Program
- Behavioral
- Lead sponsor
- Lillian Haley, PhD
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lithonia, Georgia
- Conditions
- Infection, Human Immunodeficiency Virus I, HIV Infection
- Interventions
- GW873140, Combivir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 27
- States / cities
- Bakersfield, California • Beverly Hills, California • Los Angeles, California + 21 more